FDA Holds Workshop on Testosterone Therapy for Menopausal Women Amid Lack of Approved Products
Solo los hechos

FDA Holds Workshop on Testosterone Therapy for Menopausal Women Amid Lack of Approved Products

Resumen

The FDA convened a public workshop to review safety and research gaps for testosterone use in menopausal women, a treatment that currently has no FDA-approved formulation and often faces insurance denials.

The U.S. Food and Drug Administration held a public workshop on Thursday to examine the evidence, safety profile and research gaps of testosterone therapy for women experiencing menopause. Because no testosterone product has received FDA approval for female use, physicians rely on off-label prescribing, custom compounding or micro-dosing male gel, practices that can lead to insurance refusals and dosing uncertainty.

Dr. Kudzai Dombo, an obstetrician-gynecologist and Menopause Society-certified practitioner in Los Angeles, said patients frequently ask whether testosterone is needed after they begin standard estrogen and progesterone regimens. She noted that current clinical guidelines endorse testosterone only for hypoactive sexual desire disorder, while data supporting benefits for energy, mood, bone health or sleep remain limited.

Without a female-specific formulation, doctors must choose between compounded creams and diluted male gel packets. Dombo described a case in which a patient measured one-tenth of a male gel packet each day, yet blood tests after three months showed no hormonal change and no symptom improvement. She added that insurance companies routinely deny coverage for off-label use, forcing patients to pay out of pocket; in one instance, a 10-month supply of male gel was cheaper than a single month of compounded cream.

"We're left to kind of decide, 'Well, what now?' It's all experimentation ... We don't have a set guideline for how to do this for women. We have to rely on the art of medicine," Dombo said.

Dombo said the FDA workshop reflects growing pressure from patients and clinicians for clearer regulatory pathways. "We’re not going to stop knocking on the door, because there are several of us who believe that women deserve to be able to have access to just what they need," she added.

Fuente

Fox News

Sigue leyendo, gratis

Crea una cuenta gratis para seguir las noticias. No se requiere tarjeta.